Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

OBJECTIVE: To assess satisfaction with the serum-free formulation of subcutaneous (sc) interferon (IFN) beta-1a among patients with relapsing multiple sclerosis (MS). METHODS: Patients with relapsing MS who had been receiving sc IFN beta-1a for at least 6 months, were transitioned to the new formula...

Descripción completa

Detalles Bibliográficos
Autores principales: Camu, William, Hadjout, Karim, Latour, Sabine, Pöhlau, Dieter, Masri, Said
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875722/
https://www.ncbi.nlm.nih.gov/pubmed/20517473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875722/
https://www.ncbi.nlm.nih.gov/pubmed/20517473

Ejemplares similares